NCT05303532 2026-04-22
ROSY-D
AstraZeneca
Phase 3 Enrolling by invitation
Clinical Trials
15 trialsNCT03907475 2026-04-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06031233 2026-03-30
MINUTE
Isala
Phase 4 Recruiting
NCT06551142 2025-12-18
PanTumor-101
GlaxoSmithKline
Phase 1 Recruiting
NCT03842228 2025-10-14
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT02671435 2025-07-22
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
Phase 1/2 Active not recruiting
NCT03847649 2025-06-11
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT03406650 2025-05-04
SAKK 06/17
Swiss Cancer Institute
Phase 2 Completed
NCT05000710 2024-12-05
CORAL-Lung
Sheba Medical Center
Phase 2 Active not recruiting
NCT03946800 2024-10-02
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT03094286 2024-06-24
Durvalumab in HIV-1 Patients With Solid Tumors
Spanish Lung Cancer Group
Phase 2 Completed
NCT03238027 2024-05-17
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
Syndax Pharmaceuticals
Phase 1 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT02556463 2018-12-19
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
MedImmune LLC
Phase 1 Terminated